close

Download the Manifesto

scroll down for the content

Building a strong European economy and cohesive European society largely depends on a healthy population. In fact, 70% of EU citizens want more to be done at EU level on healthcare1. This is why ensuring all European citizens live healthier lives must be a priority for the new legislative mandate, supported by more patient centered health systems and a smart sectorial industrial policy and pro-innovation environment.

The health of the EU’s citizens depends on all of us – patient groups, policy-makers, healthcare professionals, civil society and industry. Pooling our resources and expertise will ensure that what we do brings tangible benefits to EU citizens and strengthens the EU’s global reputation for outstanding R&D and innovation.

Together we can transform the lives of patients – it is why #WeWontRest.

The research-based pharmaceutical sector is pleased to share its vision and proposals on how to build a healthier future and brighter tomorrow for Europe.

Thanks to major steps in biopharmaceutical research and advances in prevention, screening, diagnosis and treatment, EU citizens can expect to live up to 30 years longer than they did a century ago.

Cancer death rates have fallen by 20% over the last 20 years 2.

Today, close to 30 diseases are preventable by vaccination, preventing between 2 and 3 million deaths globally per year 3.

WHAT EUROPE CAN DO

1

Drive the evolution towards patient-centered and outcomes-focused healthcare systems to allow national governments to recognise and reward innovation based on the value it brings to patients and society. This includes assessing and benchmarking EU Health Systems by using patient-relevant outcomes, with the support of digital solutions and a European harmonised distributed health data network.

2

Improve patient access in Europe by setting up a future European clinical assessment system that accelerates the process through harmonization of clinical data requirements and removal of duplicative assessments.

3

Convene a coalition for vaccination that could bring together European associations of healthcare workers to commit to increasing vaccination coverage in Europe. Establishing a European vaccination information portal would help to provide online objective, transparent and updated evidence on vaccines.

Europe is the second largest pharmaceutical market in the world and accounts for 22% of world pharmaceutical sales.

More than 80% of vaccine doses produced by companies leading in research and development are produced in Europe.4
The EU research-based pharmaceutical sector is considered to be the high-tech sector contributing the most to the EU trade balance with a trade surplus of €79.7 billion in 2017.
We employ 115,000 people in R&D alone and 750,000 in total; we invested more than €35 billion in R&D across Europe in 2017 and we plan to sustain these R&D investment levels in Europe over the next 5 years.

WHAT EUROPE CAN DO

1

Improve the position of Europe in fast-tracking breakthrough therapies which meet unmet health needs for patients and provide the European Medicines Agency the resources and flexibility to be at the forefront of regulatory excellence globally.

2

Maintain and develop Europe’s world-class intellectual property (IP) system by promoting strong IP protection, incentives and reward mechanisms for R&D, new incentives for high unmet medical needs, such as antimicrobial resistance (AMR),
and assistance for start-ups and smaller companies, including Small and Medium Sized Entreprises (SMEs).

3

Advance Europe’s smart trade agenda to promote investment and actively use trade policy to promote Europe’s regulatory and IP frameworks. Deepened trade agreements with Europe’s trading partners should also focus on start-ups and SMEs.

With over 450 million people and high healthcare standards, the EU is one of the best places in the world for clinical research.

Europe is leading in the field of Public Private Partnerships (PPPs) and can remain a global research hub if we ensure that health is a priority for the allocation of public research funds.

Thanks to collaborative efforts between public authorities, regulatory bodies, universities, hospitals, research organisations, patient organisations, and industry, outstanding research results have already helped to address unmet medical needs, improving public health and citizens’ quality of life.

WHAT EUROPE CAN DO

1

Make Europe a world leader in clinical research by fostering the adoption of new trial designs supported by digital tools and speed up implementation of the Clinical Trials Regulation to remove duplicative processes between Member States. This includes assessing whether the regulatory framework for the research-based pharmaceutical sector is fit for purpose via Better Regulation.

2

Support a flexible legal framework for a Public Private Partnership in health to foster medical R&D activities and modernized manufacturing in healthcare to tackle the challenges of the future.

3

Launch a new strategic dialogue for the EU healthcare and life sciences sectors to implement an ambitious roadmap for the future of health in Europe, working with all stakeholders to leverage the proposals contained in this Manifesto.

References:
1 Eurobarometer of the European Parliament (87.1)
2 Jönsson B et al. (2016), The cost and burden of cancer in the European Union 1995-2014;
Eur J Cancer, p. 169
3 10 facts on immunization, WHO
4 Vaccine Industry in Figures brochure